A Phase 3, Randomized, Controlled Trial of Resmetirom in NASH with Liver Fibrosis
Open accessThe DOI matches its Crossref record; 26 of the 26 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Nonalcoholic steatohepatitis (NASH) is a progressive liver disease with no approved treatment. Resmetirom is an oral, liver-directed, thyroid hormone receptor beta-selective agonist in development for the treatment of NASH with liver fibrosis. METHODS: We are conducting an ongoing phase 3 trial involving adults with biopsy-confirmed NASH and a fibrosis stage of F1B, F2, or F3 (stages range from F0 [no fibrosis] to F4 [cirrhosis]). Patients were randomly assigned in a 1:1:1 ratio to receive once-daily resmetirom at a dose of 80 mg or 100 mg or placebo. The two primary end points at week 52 were NASH resolution (including a reduction in the nonalcoholic fatty liver disease [NAFLD] activity score by ≥2 points; scores range from 0 to 8, with higher scores indicating more severe disease) with no worsening of fibrosis, and an improvement (reduction) in fibrosis by at least one stage with no worsening of the NAFLD activity score. RESULTS: Overall, 966 patients formed the primary analysis population (322 in the 80-mg resmetirom group, 323 in the 100-mg resmetirom group, and 321 in the placebo group). NASH resolution with no worsening of fibrosis was achieved in 25.9% of the patients in the 80-mg resmetirom group and 29.9% of those in the 100-mg resmetirom group, as compared with 9.7% of those in the placebo group (P<0.001 for both comparisons with placebo). Fibrosis improvement by at least one stage with no worsening of the NAFLD activity score was achieved in 24.2% of the patients in the 80-mg resmetirom group and 25.9% of those in the 100-mg resmetirom group, as compared with 14.2% of those in the placebo group (P<0.001 for both comparisons with placebo). The change in low-density lipoprotein cholesterol levels from baseline to week 24 was -13.6% in the 80-mg resmetirom group and -16.3% in the 100-mg resmetirom group, as compared with 0.1% in the placebo group (P<0.001 for both comparisons with placebo). Diarrhea and nausea were more frequent with resmetirom than with placebo. The incidence of serious adverse events was similar across trial groups: 10.9% in the 80-mg resmetirom group, 12.7% in the 100-mg resmetirom group, and 11.5% in the placebo group. CONCLUSIONS: Both the 80-mg dose and the 100-mg dose of resmetirom were superior to placebo with respect to NASH resolution and improvement in liver fibrosis by at least one stage. (Funded by Madrigal Pharmaceuticals; MAESTRO-NASH ClinicalTrials.gov number, NCT03900429.).
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source doesn’t support the claim as written.
In the citing paper
“Therefore, incretinbased medications for the treatment of MASLD could be made available, supplementing resmetirom as the only approved medication in the USA and Europe.87”
From GLP-1 receptor agonists and next-generation incretin-based medications: metabolic, cardiovascular, and renal benefits (2026) · cites this paper as [87]
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredThe cited source doesn’t support the claim as written.
In the citing paper
“Resmetirom is the first compound approved for the treatment of MASH in conjunction with diet and exercise, showing the importance of combining lifestyle changes to pharmacological treatment.91”
From Lipid metabolism in MASLD and MASH: From mechanism to the clinic (2024) · cites this paper as [91]
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“It was not until March 2024 that the U.S. Food and Drug Administration (FDA) approved the first drug, Rezdiffra, for non-alcoholic steatohepatitis (NASH) with liver fibrosis.”
From Mechanisms, efficacy, and future perspectives of cellular-based therapies for liver fibrosis/cirrhosis: focusing on mesenchymal stromal cells (2025) · cites this paper as [8]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Resmetirom, a THRβ agonist, showed antisteatogenic potential in a 36-week phase 2 RCT in people with biopsy-confirmed MASH and fibrosis, accompanied by a rise in circulating adiponectin and improved plasma lipid profile [210,211].”
From Obesity and MASLD: Is weight loss the (only) key to treat metabolic liver disease? (2024) · cites this paper as [211]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“About 14% of participants in the MAESTRO-NASH trial were on GLP1RA treatment, with stable dosage in the 6 months and stable body weight in the 3 months preceding screening liver biopsy.”
From EASL-EASD-EASO Clinical Practice Guidelines on the management of metabolic dysfunction-associated steatotic liver disease (MASLD). (2024) · cites this paper as [350]
Experimental — accuracy not yet measured
20 more claims about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Design and validation of a histological scoring system for nonalcoholic fatty liver disease†
Kleiner, D. E., Brunt, E. M., Van Natta, M., Behling, C., Contos, M. J., Cummings, O. W., Ferrell, L. D., Liu, Y., Torbenson, M. S., Unalp‐Arida, A., et al. (2005) · Hepatology · doi:10.1002/hep.20701 · Cited by 10,791
Self-citationMach, F., Baigent, C., Catapano, A. L., Koskinas, K. C., Casula, M., Badimon, L., Chapman, M. J., De Backer, G. G., Delgado, V., Ference, B. A., et al. (2020) · European Heart Journal · doi:10.1093/eurheartj/ehz455 · Cited by 8,961
Chalasani, N., Younossi, Z., Lavine, J. E., Charlton, M., Cusi, K., Rinella, M., Harrison, S. A., Brunt, E. M., & Sanyal, A. J. (2018) · Hepatology · doi:10.1002/hep.29367 · Cited by 7,239
Self-citationAlberti, K. G. M. M., Zimmet, P., & Shaw, J. (2006) · Diabetic Medicine · doi:10.1111/j.1464-5491.2006.01858.x · Cited by 6,597
2013 ACC/AHA Guideline on the Assessment of Cardiovascular Risk
Goff, D. C., Lloyd-Jones, D. M., Bennett, G., Coady, S., D’Agostino, R. B., Gibbons, R., Greenland, P., Lackland, D. T., Levy, D., O’Donnell, C. J., et al. (2014) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2013.11.005 · Cited by 4,945
A multisociety Delphi consensus statement on new fatty liver disease nomenclature
Rinella, M. E., Lazarus, J. V., Ratziu, V., Francque, S. M., Sanyal, A. J., Kanwal, F., Romero, D., Abdelmalek, M. F., Anstee, Q. M., Arab, J. P., et al. (2023) · Hepatology · doi:10.1097/hep.0000000000000520 · Cited by 3,476
Self-citationAngulo, P., Kleiner, D. E., Dam-Larsen, S., Adams, L. A., Bjornsson, E. S., Charatcharoenwitthaya, P., Mills, P. R., Keach, J. C., Lafferty, H. D., Stahler, A., et al. (2015) · Gastroenterology · doi:10.1053/j.gastro.2015.04.043 · Cited by 2,987
Rinella, M. E., Neuschwander-Tetri, B. A., Siddiqui, M. S., Abdelmalek, M. F., Caldwell, S., Barb, D., Kleiner, D. E., & Loomba, R. (2023) · Hepatology · doi:10.1097/hep.0000000000000323 · Cited by 2,667
Self-citationEstes, C., Razavi, H., Loomba, R., Younossi, Z., & Sanyal, A. J. (2018) · Hepatology · doi:10.1002/hep.29466 · Cited by 2,399
Self-citationMechanisms and disease consequences of nonalcoholic fatty liver disease
Loomba, R., Friedman, S. L., & Shulman, G. I. (2021) · Cell · doi:10.1016/j.cell.2021.04.015 · Cited by 2,002
Self-citation
Research works printed but not linked: 2
- 24. Conduct of clinical trials of medical products during the COVID-19 public health emergency: guidance for industry, investigators, and institutional review boards. Silver Spring, MD: Food and Drug Administration, August 30, 2021 (https:// www . fda . gov/ media/ 136238/ download/ ). Goff DC Jr, Lloyd-Jones DM, Bennett G, et al. 2013 ACC/AHA guideline on the
- 3. ogy/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol 2014; 63: 2935-59.
Cited by
Items 901–1,000 of 1,003
Chuang, L. I. U., Wang, Q., Lin, Z., Li, G., EI-Aty, A. M. A., & Dang, J. (2025) · Arabian Journal of Chemistry · doi:10.25259/ajc_268_2024 · Cited by 3
Hussaini, H., Dhanjal, M. K., Abdul, R. H. M., Fadeyi, O. A., Bhatti, N. A., Rauf, M. A., Wei, C. R., & Amin, A. (2025) · Cureus · doi:10.7759/cureus.88949 · Cited by 5
“MASH has emerged as a leading cause of chronic liver disease worldwide, largely driven by the global epidemics of obesity, insulin resistance, and type 2 diabetes mellitus [2].”
Effect of resmetirom on lipid profile and adiponectin levels
Simental‐Mendía, L. E., Simental-Mendía, M. A., Barragán‐Zuñiga, L. J., & Navarro-Tinoco, L. (2025) · European Journal of Internal Medicine · doi:10.1016/j.ejim.2025.106440 · Cited by 3
Xiong, Y., Luo, W., Ye, J., Cui, Y., Zheng, X., Jin, L., Lou, S., Zhang, Q., Wang, A., Fang, Y., et al. (2025) · British Journal of Pharmacology · doi:10.1111/bph.70161 · Cited by 3
“Recently, resmetirom became the first drug approved by the FDA for the treatment of MASH, receiving approval in March 2024 (Harrison et al., 2024; Keam, 2024).”
López-Herrador, S., Torres‐Rusillo, S., González‐García, P., Jiménez-Sánchez, L., Corral-Sarasa, J., Bakkali, M., Díaz-Casado, M. E., & López, L. C. (2025) · Pharmacological Research · doi:10.1016/j.phrs.2025.107906 · Cited by 4
Wang, X., Zheng, T., Liu, B., Pei, Z., Meng, K., & Ling, C. (2025) · JMIR Formative Research · doi:10.2196/66503 · Cited by 3
“…encompassing lifestyle modifications (eg, dietary adjustments [7-10] and physical activity) and pharmacological interventions, such as resmetirom [11], antidiabetic agents (glucagon-like peptide-1 agonists [12] and pioglitazone [13]), and vitamin E [14,15], which have shown efficacy in clinical…”
Arredouani, A. (2025) · Diabetologia · doi:10.1007/s00125-025-06527-y · Cited by 3
“Despite its profound public health burden, only one pharmacological therapy, resmetirom, has received US Food and Drug Administration (FDA) approval for the treatment of metabolic dysfunction-associated steatohepatitis (MASH) with liver fibrosis [2].”
Spann, A., Bishop, K. M., Marbach, S., Ji, X., Slaughter, J. C., Weitkamp, A. O., Stenner, S. P., Nelson, S. D., Lopez, C., Theobald, C. N., et al. (2025) · Hepatology Communications · doi:10.1097/hc9.0000000000000794 · Cited by 4
“[10,11] Furthermore, in patients with advanced fibrosis or cirrhosis due to MASH, lack of awareness can be detrimental due to a real risk of missing incident HCC developing in this patient population.”
Masrour, O., Ehrhard, F., Guillaume, M., Boursier, J., Gournay, J., Aziz, K., Schnee, M., Garlantézec, R., de Lédinghen, V., Morçet, J., et al. (2025) · JHEP Reports · doi:10.1016/j.jhepr.2025.101589 · Cited by 6
“25 These developments raise important considerations regarding both patient follow-up and treatment efficacy evaluation.”
Charfi, H., Massetto, B., Fitzgerald, M., Le, K. N., Wang, S., Kan‐Eng, I., Venkatraman, M., Mohammad, N., Blatt, L. M., Lin, T., et al. (2025) · Clinical Pharmacology in Drug Development · doi:10.1002/cpdd.1606 · Cited by 3
Kaya, E., Yilmaz, Y., & Alkhouri, N. (2025) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2025.2566258 · Cited by 6
“Resmetirom – a thyroid hormone receptor-β (THR-β) agonist – became the first conditionally approved drug for the treatment of MASLD, specifically targeting patients with MASH and stage F2–F3 fibrosis (at-risk MASH) [12].”
InfluentialSelf-citationStupalkowska, W., Henney, A. E., Sheu, E. G., Alam, U., & Cuthbertson, D. J. (2025) · Diabetes Obesity and Metabolism · doi:10.1111/dom.70173 · Cited by 7
“In recent years, there have been several pharmacological agents showing promising results in SLD 50,51 with glucagon-like peptide 1 receptor agonists (GLP-1RA) revolutionizing the management of obesity and T2D and consequently changing the trends in MBS utilization.”
Alsharif, O., & Rombouts, K. (2025) · npj gut and liver. · doi:10.1038/s44355-025-00037-9 · Cited by 3
Isotype-selective roles of hepatic acetyl-CoA carboxylases in a mouse model of fatty liver disease
Beretta, M., Vancuylenburg, C. S., Shrestha, R., Olzomer, E. M., Osborne, B., Zhou, M., Zhang, S., Hargreaves, A., Byrne, F. L., & Hoehn, K. L. (2025) · Molecular Metabolism · doi:10.1016/j.molmet.2025.102264 · Cited by 6
“Semaglutide is the second FDA-approved MASH treatment following accelerated approval of the thyroid hormone receptor-β agonist resmetirom (Rezdiffra) in March 2024 for the treatment of MASH with moderate fibrosis (F2 — F3) [10,11].”
InfluentialSemaglutide for the treatment of MASH: reaching into the ESSENCE of cardio-metabolic health?
Mademlis, C., Patoulias, D., Koufakis, T., Teperikidis, E., Γιουλεμέ, Ό., & Doumas, M. N. (2025) · Expert Review of Clinical Pharmacology · doi:10.1080/17512433.2025.2573785 · Cited by 3
“Compared to resmetirom – the first FDA-approved agent for MASH with fibrosis – semaglutide offers the advantage of broad cardiometabolic improvements, which may be particularly relevant in patients with obesity or type 2 diabetes [17].”
Jiao, L., Yang, Y., Huang, Y., Shang, H., Liu, Z., Li, W., Sun, J., Yang, H., Hu, J., & Wan, Y. (2025) · Environmental Science & Technology · doi:10.1021/acs.est.5c07061 · Cited by 3
Palmer, M., Arman, A. C., Lawitz, E., Sanchez, W. E., Mittal, S., Hassanein, T., Hansen, S. G., Meidling, J., Cunningham, B., Buss, N., et al. (2025) · Liver international communications. · doi:10.1002/lci2.70028 · Cited by 4
Potential hepatoprotective effect and mechanisms of Ganoderma lucidum polysaccharides
Wang, Y., Sun, Y., Li, B., Xu, J., Wang, S., Xu, H., Jiang, Z., & Wu, X. (2025) · Journal of Future Foods · doi:10.1016/j.jfutfo.2025.07.024 · Cited by 6
Zou, X., Yang, Y., Liu, X., Qi, W., Zao, X., Li, X., & Ye, Y. (2025) · Pharmacological Research · doi:10.1016/j.phrs.2025.108024 · Cited by 6
An analysis of safety data from the first year of resmetirom
Kudaravalli, P., Andrews, M. B., & Adler, D. G. (2025) · Gastroenterology report · doi:10.1093/gastro/goaf097 · Cited by 3
Wang, Y., & Peng, J. (2025) · Pharmacological Research · doi:10.1016/j.phrs.2025.108054 · Cited by 3
Zacharia, G. S., Ashraf, M. H., Sosa, F., Jacob, A., & Patel, H. (2025) · World Journal of Gastrointestinal Pharmacology and Therapeutics · doi:10.4292/wjgpt.v16.i4.110827 · Cited by 3
Dahl, K., Friedrichsen, M. H., Ribel‐Madsen, R., Hansen, J. S., Clausen, J. O., Axelsen, M. B., Palle, M. S., Lippert, S. L., Björkdahl, O., Toubro, S., et al. (2025) · Clinical and Translational Science · doi:10.1111/cts.70435 · Cited by 3
Ali, B., Samuel, R. E., Kramer, J. R., Li, L., Yu, X., Cao, Y., Desiderio, R., Cholankeril, G. T., Asch, S. M., El‐Serag, H. B., et al. (2026) · Hepatology Communications · doi:10.1097/hc9.0000000000000878 · Cited by 4
“[7,8] Measuring the burden of cirrhosis and its complications in MASLD is crucial, as these data can provide a critical insight into the magnitude of the problem and inform changes in the pattern of care delivery to patients with MASLD.”
Yeo, Y. H., Ho, H. J., Huang, T., Lee, T., Yang, J. D., Cholankeril, G. T., Chen, C., Yang, H.-I., Chen, C., Chang, H.-C., et al. (2026) · Liver Cancer · doi:10.1159/000550360 · Cited by 3
“However, as of now, only resmetirom and semaglutide have received accelerated FDA approval for treating individuals with metabolic dysfunction-associated steatohepatitis and fibrosis stages F2 and F3 [6].”
A microphysiological model of human MASLD reveals paradoxical response to resmetirom
Hellen, D. J., Ungerleider, J. L., Tevonian, E. N., Sphabmixay, P., Roy, P., Meimetis, N., Presutti, F., Williams, A. M., Ogi, R., Lewis, C. A., et al. (2026) · Communications Biology · doi:10.1038/s42003-025-09484-9 · Cited by 4
Zhu, B. J. (2026) · Frontiers in Endocrinology · doi:10.3389/fendo.2025.1753393 · Cited by 3
Pennisi, G., Infantino, G., Maria, G. D., Tsochatzis, E. A., Bugianesi, E., Yoneda, M., Zheng, M., Hagström, H., Boursier, J., Calleja, J. L., et al. (2026) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2026.01.020 · Cited by 7
Self-citationZhai, D., Ni, J., Shao, X., Zhao, W., Chen, Y., Fan, K., Li, J., Shen, Y., Lin, A., Hu, W., et al. (2026) · Hepatology · doi:10.1097/hep.0000000000001708 · Cited by 4
Ogbu, C. E., Ogbu, S. C., Ogbu, C. P., & Umerah, C. (2026) · iLiver · doi:10.1016/j.iliver.2026.100222 · Cited by 4
“4,5 Since dyslipidemia and adverse lipidomic signatures are linked to faster epigenetic aging, 71,72 resmetirom's cardiometabolic effects may intersect with pathways influencing BA acceleration.”
Hepatocyte PLAGL2 deficiency alleviates MASH through MYD88-licensed inactivation of inflammasome
Duan, R., Wang, X., Wang, Q., Zhou, X., Gao, S., Sun, Y., Feng, Q., Li, Z., Yang, Z., Ding, J., et al. (2026) · Cell Reports · doi:10.1016/j.celrep.2026.116942 · Cited by 4
Cao, W.-J., Su, R., Fu, H.-L., Wu, J.-J., Huang, L.-S., Liu, F.-F., Liu, J., Jiang, Z.-P., Xu, C.-J., Rao, Y., et al. (2026) · Experimental & Molecular Medicine · doi:10.1038/s12276-026-01648-9 · Cited by 4
Laurence, A., Gandhi, S., Nylén, E., & Sen, S. (2026) · Endocrine Practice · doi:10.1016/j.eprac.2026.02.011 · Cited by 3
Luo, Z., Wu, J., Xu, B., Wu, D., Zhong, Y., Hao, M., Xu, Y., Yang, J., Wang, Y., Lauschke, V. M., et al. (2026) · Biomaterials · doi:10.1016/j.biomaterials.2026.124089 · Cited by 3
Venkatesh, S. K. (2026) · Expert Review of Gastroenterology & Hepatology · doi:10.1080/17474124.2026.2636184 · Cited by 3
“…such as glucagon-like peptide-1 (GLP-1) receptor agonists (liraglutide, semaglutide) and thyroid hormone receptor-ß (THR-ß) agonists (Resmetirom) are now front-line options due to their ability to improve insulin sensitivity, reduce hepa-tic steatosis, and achieve histologic resolution [13,14].”
Autoimmunity, diet and autophagy
Blaise, S. A., & Muller, S. (2026) · Autoimmunity Reviews · doi:10.1016/j.autrev.2026.104040 · Cited by 3
Li, D., Zhang, L., Li, Y., Wu, J., Mou, Y., He, Y., Zhou, T., Gong, Q., Ma, L., Xu, Y., et al. (2026) · Clinical Epigenetics · doi:10.1186/s13148-026-02111-2 · Cited by 4
“Thus, there is an urgent unmet need for more effective therapeutic strategies [8–10].”
Role of miRNA signalling in the pathogenesis of MASLD
Cheng, S., Hao, J., & Qin, H.-Y. (2026) · Frontiers in Pharmacology · doi:10.3389/fphar.2026.1756805 · Cited by 3
“…growth factor 21 (FGF21) analogs (e.g., pegbelfermin), and farnesoid X receptor (FXR) modulators, while FDA-approved new drugs such as resmetirom target metabolic regulation, anti-inflammatory effects, or anti-fibrotic mechanisms (Stojsavljevic-Shapeski et al., 2020; Harrison et al., 2024).”
Cobbold, J., Miller, H., Hallsworth, K., Manousou, P., Marjot, T., Allison, M. E., Anstee, Q. M., Armstrong, M., Avery, L., Azzu, V., et al. (2026) · The Lancet. Gastroenterology & hepatology · doi:10.1016/s2468-1253(26)00077-4 · Cited by 6
Self-citationUnified platform for multiplex immunofluorescence across liver tissues and engineered models
Leonardi, B. F., Guo, Y., Amiridze, N., Lan, T., Ahmed, Y. A., Berger, H., Tacke, F., Kohlhepp, M. S., & Guillot, A. (2026) · eGastroenterology · doi:10.1136/egastro-2026-100379 · Cited by 3
The immunometabolic nature of MASH: framing immune cells within metabolic dysfunction
González-Serrano, S., Onoiu, A.-I., Jiménez-Franco, A., Cambra-Cortés, V., Camps, J., & Joven, J. (2026) · Frontiers in Immunology · doi:10.3389/fimmu.2026.1797949 · Cited by 4
Akuta, N., Kogiso, T., Ikejima, K., Otsuka, M., Kawaguchi, T., Kawanaka, M., Takahashi, H., Tamaki, N., Nakagawa, H., 疋田隼人, et al. (2026) · Hepatology Research · doi:10.1111/hepr.70188 · Cited by 8
“• Resmetirom has demonstrated efficacy in the treatment of MASH in patients with fibrosis stages F2–F3 [109].”
Richard, K. S. E., Rohilla, S., Gade, R., Arias, F., & Rom, O. (2026) · Current Atherosclerosis Reports · doi:10.1007/s11883-026-01425-z · Cited by 4
“This selective thyroid hormone receptor–β agonist enhances hepatic FAO and mitochondrial function, reduces intrahepatic fat and fibrosis, and simultaneously improves the systemic lipid profile by lowering LDL-cholesterol and triglycerides [100 ].”
Repurposing Resmetirom to Suppress MASLD/MASH-HCC in the Dysmetabolic Era
Lonardo, A., Zheng, M., & Weiskirchen, R. (2026) · Oncology and Therapy · doi:10.1007/s40487-026-00442-x · Cited by 4
Guo, J., Xiang, Z., Hu, F.-F., Zhang, S.-X., Han, W.-J., Ding, X., Wang, X., Ye, M.-L., Chen, J., Rao, T., et al. (2026) · mSystems · doi:10.1128/msystems.00292-26 · Cited by 4
“Although the recent approval of the thyroid-hormone-receptor-β agonist Resmetirom marks a therapeutic milestone (6), effective options remain scarce, largely because of a paucity of druggable targets.”
The thyroid-liver axis in MASLD: From metabolic control to clinical translation
Chouik, Y., Caussy, C., & Tacke, F. (2026) · Med · doi:10.1016/j.medj.2026.101173 · Cited by 4
Tang, M., Ma, Y., & Wang, Y. (2026) · Frontiers in Endocrinology · doi:10.3389/fendo.2026.1829315 · Cited by 3
Capuccio, S., Privitera, G., Scilletta, S., Rocca, F. L., Marco, M. D., Scicali, R., Pino, A. D., Piro, S., & Russello, M. (2026) · Liver International · doi:10.1111/liv.70431 · Cited by 5
“Firstly, there is a lack of validated predictive biomarkers to identify which patients are most likely to respond, complicating patient selection [84, 86].”
Impaired glycoRNA biogenesis in metabolic-dysfunction associated steatotic liver disease
Dong, C., Zhong, X., Peng, Q., Müller, Z., Beimdiek, J., Splith, K., Feldbrügge, L., Cantz, T., Singh, M. K., Buettner, F. F. R., et al. (2026) · Journal of Hepatology · doi:10.1016/j.jhep.2026.04.034 · Cited by 4
Newer and novel antidiabetic drug classes across the cardiovascular–kidney–metabolic continuum
Stefanakis, K., Karakasis, P., Vasdeki, D., Popovic, D. S., Patoulias, D., Rizzo, M., & Mantzoros, C. S. (2026) · Endocrine Reviews · doi:10.1210/endrev/bnag022 · Cited by 6
Pharmacological treatment of MASH
Stefan, N., & Targher, G. (2026) · Diabetologia · doi:10.1007/s00125-026-06796-1 · Cited by 6
“Resmetirom improved plasma concentrations of LDL-cholesterol, triacylglycerol and lipoprotein(a) but had neutral effects on body weight, HbA 1c and insulin resistance and did not induce adverse endocrine events, tachyarrhythmias or major changes in bone mineral density [51].”
The new era of MASH pharmacotherapy: a comprehensive review of FDA-approved and emerging agents
Qasim, A., Alataa, R., Veena, F., & Shehi, E. (2026) · Frontiers in Gastroenterology · doi:10.3389/fgstr.2026.1850915 · Cited by 4
Repurposing of the analgesic Neurotropin for MASLD/MASH treatment
Tsuchiya, T., Kim, S. Y., Matsuda, M., Kim, J., Stotland, A. B., Naiki, M., & Seki, E. (2024) · Hepatology Communications · doi:10.1097/hc9.0000000000000480 · Cited by 3
“[5] Various new drugs are still under investigation for treating MASLD.”
BackgroundKitsios, K., Trakatelli, C., Antza, C., Triantafyllou, Α., Sarigianni, M., & Kotsis, V. (2024) · Metabolic Syndrome and Related Disorders · doi:10.1089/met.2024.0059 · Cited by 3
Bejitual, E., Awais, M. F., Modi, D., Gul, U., Obeidat, K., Ahmed, N., Waheed, M. D., & Hirani, S. (2024) · Cureus · doi:10.7759/cureus.70859 · Cited by 7
“Sources: [12-14]”
ResultDutta, P., Annoor, A., Dey, P., Sultana, J., Mokbul, M. I., Naurin, S. A., Roy, R., Simona, S. Y., Dutta, J., Mazumder, T., et al. (2024) · Cureus · doi:10.7759/cureus.71095 · Cited by 3
Zhang, J., Wang, H., Wang, Q., Mo, J., Fu, L., & Peng, S. (2024) · Mammalian Genome · doi:10.1007/s00335-024-10078-9 · Cited by 3
Chen, C., Zhou, X., Cheng, W., Li, X., Zhang, B., Tu, J., Meng, J., Peng, Y., Duan, X., Yu, Q.-M., et al. (2024) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2024.107940 · Cited by 3
Enhancing Regulatory T cell function by mevalonate pathway inhibition prevents liver fibrosis
Bae, A.-N., Lee, H., Yang, H., Mukherjee, S., Im, S., Lee, J., & Park, J. H. (2024) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2024.151094 · Cited by 4
Alnimer, L., Arellano, D., Brombosz, E. W., & Noureddin, M. (2024) · Liver Transplantation · doi:10.1097/lvt.0000000000000544 · Cited by 5
Self-citationNovel dynamic and static biomarkers for the assessment of liver disease severity in MASLD
Amato, F., Marano, M., Gjini, K., VAIRA, L., Bugianesi, E., & Armandi, A. (2024) · Minerva Biotechnology and Biomolecular Research · doi:10.23736/s2724-542x.24.03186-9 · Cited by 4
Yu, N.-R., Huang, S., Deng, Z., Wang, J., Shen, Y., Leng, Y., & Zhao, Q. (2025) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2025.108132 · Cited by 3
Dinerman, S., & Shu, Y. (2025) · International Journal of Translational Medicine · doi:10.3390/ijtm5010007 · Cited by 6
“…worsening fibrosis (25.9% of patients with 80 mg and 25.9% with 100 mg treatment vs. 14.2% with placebo; p < 0.001, n = 955), its primary endpoints were only from one year of treatment, hindering our ability to assess the long-term toxicity potential from repeated use beyond one year [8,10].”
InfluentialRiechelmann-Casarin, L., Valente, L. C., Otton, R., Barbisan, L. F., & Romualdo, G. R. (2025) · Environmental Toxicology and Pharmacology · doi:10.1016/j.etap.2025.104705 · Cited by 7
Drzewicka, K., Głuchowska, K. M., Mlącki, M., Hofman, B., Tuszyńska, I., Ryan, T. A. J., Piwowar, K., Wilczyński, B., Dymkowska, D., Grzybowski, M. M., et al. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1544973 · Cited by 3
Choi, R., Vemuri, J. P., Poloju, A., Raj, R., Mehta, A., Asgharpour, A., Siddiqui, M. S., & Majety, P. (2025) · Endocrines · doi:10.3390/endocrines6020027 · Cited by 4
“The MAESTRO MASH phase 3 trial showed that resmetirom (80 mg and 100 mg) improved MASH resolution without fibrosis worsening (25.9–29.9% vs. 9.7% placebo, p 0.001) and fibrosis by at least 1 stage (24.2–25.9% vs. 14.2% placebo) [116].”
InfluentialEvolving Role of GLP-1 Therapies in Liver Disease
Lindsay, M., Arndt, G., Wieland, A. C., & Jensen, T. (2025) · Current Gastroenterology Reports · doi:10.1007/s11894-025-00988-2 · Cited by 3
“In 2024, Resmetirom, a Thyroid Beta Receptor Agonist, became the first FDA approved treatment for “at risk” MASH after reaching critical primary endpoints of both reversal of 1 stage of fibrosis without worsening of MASH or reversal of MASH compared to placebo [4].”
Luong, T. V., Tran, H., Thi, B. N. C., Vu, H. M., Le, T., Le, T., Thi, H. N., Nguyen, H. M., Doan, T. C., Ho, A. B., et al. (2025) · World Journal of Cardiology · doi:10.4330/wjc.v17.i7.107751 · Cited by 5
Higher plasma dicarbonyl levels are associated with liver fibrosis in obese individuals
Akinrimisi, O. I., Koning, M., Scheijen, J. L. J. M., Meijnikman, A. S., Sindhunata, D. P., Bruin, S. C., van de Laar, A. W. J. M., Franken, R. J., Acherman, Y. I. Z., Gerdes, V. E. A., et al. (2025) · Diabetes Obesity and Metabolism · doi:10.1111/dom.16643 · Cited by 2
“50 Several safe and readily available inhibitors of MGO formation have now been identified, such as the vitamer pyridoxamine, which has promising MGO-lowering and anti-inflammatory effects in mice 52 and people.”
Zatta, R., da Silva, L. S., Felga, G. E. G., & Pimentel, C. F. M. G. (2025) · World Journal of Hepatology · doi:10.4254/wjh.v17.i7.107837 · Cited by 3
Liang, J., Gu, Y., Hu, L., Qu, H., Li, N., Xia, C., Feng, L., Li, Q., Hai, L., Yang, Y., et al. (2025) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.5c00994 · Cited by 5
Hancock, M., Beyer, C., Fuchs, M., Harisinghani, M. G., Jalal, P. K., Ndaa, M., Samala, N. R., Vargas, J. D., & Jayaswal, A. N. A. (2025) · Journal of Medical Economics · doi:10.1080/13696998.2025.2550113 · Cited by 3
“During the MAESTRO-NASH trial 28 , patients were considered to have achieved the study primary end-points if they exhibited 1.”
Kim, J. W., Raggi, P., Carreau, A., Wharton, S., CHENG, A. Y. Y., & Swain, M. G. (2025) · Diabetes Obesity and Metabolism · doi:10.1111/dom.70117 · Cited by 6
Huang, C., Wang, C.-L., Wu, V. C., Hsieh, Y., Wu, C.-L., Zeng, Z.-F., Huang, Y., Hsu, C., Chien, R., & Chang, S. (2025) · Annals of Medicine · doi:10.1080/07853890.2025.2573146 · Cited by 7
“Notably, Resmetirom, a thyroid hormone receptor-β agonist, has been approved for non-alcoholic steatohepatitis (NASH) patients with moderate to advanced liver fibrosis due to its efficacy in improving steatohepatitis and fibrosis [8,9].”
Low Rates of MASLD Screening in Young Adults With Type 2 Diabetes: A Retrospective Cohort Study
de Crecy, C., yang, Q., Liu, M., Yin, R., & Sharma, A. R. (2025) · Journal of the Endocrine Society · doi:10.1210/jendso/bvaf223 · Cited by 2
“Recent advances have led to the approval semaglutide (44) and resmetirom (7) for MASH fibrosis.”
Design and Discovery of a Potent and Selective Inhibitor of Integrin αvβ1
Sabat, M. P., Carney, D. W., Hernández‐Torres, G., Gibson, T., Balakrishna, D., Zou, H., Xu, R., Chen, C., de Jong, R., Dougan, D. R., et al. (2024) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.4c00743 · Cited by 4
From O’Shaughnessy to opportunity: innovating Hepatology Trials in the UK
Tavabie, O. D., Enever, Y., Green, D., Crisp, H., Tsochatzis, E. A., Gander, A., Mansour, D., Hebditch, V., Adams, J., Ashbourn, A., et al. (2024) · Frontline Gastroenterology · doi:10.1136/flgastro-2024-102710 · Cited by 3
Computational study of novel natural agonists targeting farnesoid X receptor
Hu, X., Ge, J., & Wen, Y. (2024) · Scientific Reports · doi:10.1038/s41598-024-68526-0 · Cited by 5
Drug treatments to prevent first decompensation in cirrhosis
Kezer, C. A., Berzigotti, A., Fortune, B. E., & Simonetto, D. A. (2024) · Hepatology · doi:10.1097/hep.0000000000001117 · Cited by 4
Bansal, M. B. (2024) · Elsevier eBooks · doi:10.1016/b978-0-443-26710-9.00008-0 · Cited by 3
Self-citationKim, Y., Medicis, J. J., Davis, M. R., Nunag, D., & Gish, R. G. (2024) · Journal of Comparative Effectiveness Research · doi:10.57264/cer-2024-0096 · Cited by 5
Metabolic dysfunction-associated steatotic liver disease
Chen, C., & Liao, D.-M. (2024) · 童綜合醫學雜誌 · doi:10.4103/etmj.etmj-d-24-00019 · Cited by 3
Basile, A. O., Verma, A., Tang, L. A., Serper, M., Scanga, A. E., Farrell, A., Destin, B., Carr, R. M., Anyanwu‐Ofili, A., Rajagopal, G., et al. (2024) · Clinical and Translational Science · doi:10.1111/cts.70105 · Cited by 3
Chen, X., Huang, J., You, Y., Xue, H., Wu, L., Zeng, D., Xing, Q., Wu, M., Wang, M.-F., Pan, J., et al. (2025) · Clinical Nutrition · doi:10.1016/j.clnu.2024.12.033 · Cited by 3
Niezen, S., Morgan, T. R. M., Scott, D., Yakovchenko, V., Patton, H. M., Spoutz, P. M., Yao, Y., Baffy, G., Fuchs, M. A., Bajaj, J. S., et al. (2025) · The American Journal of Gastroenterology · doi:10.14309/ajg.0000000000003312 · Cited by 3
Williams, D. M., Nagaraj, J., Stephens, J. W., & Min, T. (2025) · touchREVIEWS in Endocrinology · doi:10.17925/ee.2025.21.1.4 · Cited by 3
Optimization of Cyclophilin B-Targeted Tri-vector Inhibitors for Novel MASH Treatments
Kouridaki, M.-E., Gillespie, J., Robinson, J., Mathie, T., Bain, L., McArthur, D. R., Morrison, A. J., Greenslade, D. B., Papadourakis, M., Maj, K., et al. (2025) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.5c00301 · Cited by 4
Resolvin D1-mediated cellular crosstalk protects against MASH
Navarro‐Corcuera, A., Zhu, Y., Ma, F., Gupta, N., Asplund, H., Cogliati, B., Chipuk, J. E., Rom, O., Friedman, S. L., Sansbury, B. E., et al. (2025) · JHEP Reports · doi:10.1016/j.jhepr.2025.101454 · Cited by 11
Oleocanthalic acid improves MASH features via a NOX1-dependent mechanism
Frión-Herrera, Y., Zanotto, I., Colognesi, M., Signor, A., Cuffaro, D., Chilin, A., Macchia, M., Marzaro, G., Digiacomo, M., Gabbia, D., et al. (2025) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2025.177847 · Cited by 3
Gripshover, T. C., Treves, R. S., & Hardesty, J. (2025) · American Journal Of Pathology · doi:10.1016/j.ajpath.2025.05.013 · Cited by 3
Sebastiani, G., Raggi, P., & Guaraldi, G. (2025) · Canadian Journal of Cardiology · doi:10.1016/j.cjca.2025.06.075 · Cited by 8
Armisen, J., Flor, A. W., Eriksson, J., Nelander, K., Bhattacharya, C. S., Sunnåker, M., Carter, D., Trebski, M., Gårdmark, E., Aurell, M., et al. (2025) · Liver International · doi:10.1111/liv.70406 · Cited by 4
“While ALT has been criticised as a relatively insensitive and non-specific marker in MASH [22], several prior studies involving effective agents have consistently reported robust ALT reductions in parallel with histological improvement [23–26].”
Fujii, H., Iwaki, M., & Kamada, Y. (2024) · Clinical and Molecular Hepatology · doi:10.3350/cmh.2024.0214 · Cited by 2
Investigational new drug approval of DA-1241: what we know about GPR119 targeting for MASH therapy?
Smadi, K. A., Qureshi, A., Ashouri, B., & Kayali, Z. (2024) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2024.2388592 · Cited by 3
“The dual primary end point of any treatment of MASH is to improve fibrosis without worsening steatosis and to improve the steatosis without worsening the fibrosis [5].”
InfluentialBeyond resmetirom approval for NAFLD: what has to be done?
Ezhilarasan, D. (2024) · Drug Discovery Today · doi:10.1016/j.drudis.2024.104185 · Cited by 3
Lima, L. C. V., Al‐Sharif, L., & de Souza, M. H. G. (2025) · Trends in Cardiovascular Medicine · doi:10.1016/j.tcm.2025.01.003 · Cited by 3
Determining Cirrhosis Status in Candidates for Resmetirom
Noureddin, M., Bansal, M. B., & Rinella, M. E. (2025) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2025.04.022 · Cited by 3
Self-citationPan, X., Gao, T., & Wang, B. (2025) · Cell & Bioscience · doi:10.1186/s13578-025-01520-9 · Cited by 2
“Nevertheless, more studies are required to ascertain its long-term safety and feasibility [8].”
Bobo, J. F. G., Keith, B. A., Marsden, J. E., Zhang, J., & Schreiner, A. D. (2024) · The American Journal of the Medical Sciences · doi:10.1016/j.amjms.2024.07.028 · Cited by 2
Mouse Models for the Study of Liver Fibrosis Regression In Vivo and Ex Vivo
Schönke, M., & Rensen, P. C. N. (2024) · Journal of Clinical and Translational Hepatology · doi:10.14218/jcth.2024.00212 · Cited by 13
Metadata
- Authors
- Harrison, S. A., Bedossa, P., Guy, C. D., Schattenberg, J. M., Loomba, R., Taub, R., Labriola, D., Moussa, S. E., Neff, G. W., Rinella, M. E., Anstee, Q. M., Abdelmalek, M. F., Younossi, Z., Baum, S. J., Francque, S., Charlton, M. R., Newsome, P. N., Lanthier, N., Schiefke, I., Mangia, A., Pericàs, J. M., Patil, R., Sanyal, A. J., Noureddin, M., Bansal, M. B., Alkhouri, N., Castera, L., Rudraraju, M., & Ratziu, V.
- Affiliations
- University Hospitals Birmingham NHS Foundation Trust (GB)
- From the University of Oxford, Oxford (S.A.H.), the Translational and Clinical Research Institute, Faculty of Medical Sciences, Newcastle University, Newcastle upon Tyne (Q.M.A.), and the National Institute for Health Research, Biomedical Research Centre at University Hospitals Birmingham NHS Foundation Trust and the University of Birmingham, Birmingham (P.N.N.) — all in the United Kingdom; Pinnacle Clinical Research, San Antonio (S.A.H., M.R.), South Texas Research Institute, Edinburg (R.P.), and Houston Methodist Hospital, Houston Research Institute, Houston (M.N.) — all in Texas; Liverpat and University of Paris (P.B.), INSERM, Unité Mixte de Recherche Scientifique (UMRS) 1139, Centre de Recherche sur l’Inflammation (L.C.), and Sorbonne Université, ICAN Institute for Cardiometabolism and Nutrition, Assistance Publique–Hôpitaux de Paris (APHP), INSERM, UMRS 1138, Centre de Recherche des Cordeliers (V.R.), Paris, and Université Paris-Cité, Department of Hepatology, Beaujon Hospital, APHP, Clichy (L.C.) — ...
- Universitat Autònoma de Barcelona (ES)
- Houston Methodist (US)
- ORCID
- Harrison, Stephen A.
- Guy, Cynthia D.
- Schattenberg, Jörn M.
- Loomba, Rohit
- Taub, Rebecca
- Neff, Guy W.
- Rinella, Mary E.
- Anstee, Quentin M.
- Abdelmalek, Manal F.
- Younossi, Zobair
- Baum, Seth J.
- Francque, Sven
- Charlton, Michael R.
- Newsome, Philip N.
- Lanthier, Nicolas
- Mangia, Alessandra
- Pericàs, Juan M.
- Patil, Rashmee
- Sanyal, Arun J.
- Noureddin, Mazen
- Bansal, Meena B.
- Alkhouri, Naim
- Rudraraju, Madhavi
- Ratziu, Vlad
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2024-02-08
- Volume
- 390
- Issue
- 6
- Pages
- 497-509
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W4391592880
- Cited by
- 2,084
- References
- 26
- Citations by year
- 2026: 797 · 2025: 807 · 2024: 478
- FWCI
- 635.31
- Type
- journal article
- Language
- en
- Open access
- Licence
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- University of Birmingham Research Portal (University of Birmingham) (publishedVersion, other-oa)
- IRIS Research product catalog (Sapienza University of Rome) (submittedVersion, other-oa)
- HAL (submittedVersion)
- Digital Access to Libraries (submittedVersion, other-oa)
- Digital Access to Libraries (submittedVersion)
- VUBIR (Vrije Universiteit Brussel) (submittedVersion)
- Open Access CRIS of the University of Bern
- Funders
- Madrigal Pharmaceuticals
- Topics
- Health Sciences › Medicine › Hepatology › Liver Disease Diagnosis and Treatment
- Health Sciences › Medicine › Hepatology › Liver physiology and pathology
- Health Sciences › Medicine › Hepatology › Liver Diseases and Immunity
- Keywords
- resmetirom, nonalcoholic steatohepatitis, liver fibrosis, thyroid hormone receptor beta agonist, NASH resolution, fibrosis regression, NAFLD activity score, LDL cholesterol, triglycerides, cirrhosis prevention, drug safety and tolerability
- MeSH terms
- Adult, Biopsy, Dose-Response Relationship, Drug, Double-Blind Method, Humans, Liver, Liver Cirrhosis, Pyridazines, Uracil, Treatment Outcome, Thyroid Hormone Receptors beta, Non-alcoholic Fatty Liver Disease
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.